Dolby Laboratories (DLB) has disclosed a new risk, in the Corporate Activity and Growth category.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Dolby Laboratories faces significant business risks stemming from its dependence on licensees and OEMs to incorporate its technologies into their products. As most of these agreements are non-exclusive and lack mandatory usage terms, Dolby’s revenue is vulnerable if partners opt not to use their technologies or experience reduced sales. Additionally, economic factors such as semiconductor shortages and weakened consumer spending may further jeopardize revenue streams, especially as many of the products utilizing Dolby’s technologies are discretionary consumer goods. The potential loss of key licensees or customers, coupled with shifts in market demand, underscores the company’s exposure to external market fluctuations and competitive pressures.
Overall, Wall Street has a Moderate Buy consensus rating on DLB stock based on 2 Buys.
To learn more about Dolby Laboratories’ risk factors, click here.